Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Endometrial Cancer · Cancer of Endometrium · Carcinoma of Endometrium · Endometrial Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (National Cancer Institute Referral Office) · NCIMO_Referrals@mail.nih.gov · 888-624-1937
Study leads
Hoyoung M Maeng, M.D.
Principal Investigator
National Cancer Institute (NCI)